Related Experiment Video

Updated: Mar 8, 2026

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
06:38

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

Published on: April 12, 2017

14.4K

Functional PTGS2 polymorphism-based models as novel predictive markers in metastatic renal cell carcinoma patients

Arancha Cebrián1, Teresa Gómez Del Pulgar1, María José Méndez-Vidal2

  • 1Fundación Jiménez Díaz University Hospital, Madrid, Spain.

Scientific Reports
|January 25, 2017
PubMed

Insights

This study identifies specific genetic markers (SNPs) that predict treatment response in metastatic renal cell carcinoma (mRCC) patients receiving sunitinib. These findings may lead to improved patient management and personalized cancer therapy.

Area of Science:

  • Oncology
  • Pharmacogenomics
  • Genetics

Background:

  • Sunitinib is a standard treatment for metastatic renal cell carcinoma (mRCC).
  • Predictive biomarkers for sunitinib response are needed for clinical application.
  • Current biomarkers for sunitinib efficacy in mRCC are lacking.

Purpose of the Study:

  • To investigate single nucleotide polymorphisms (SNPs) in genes related to sunitinib's mechanism of action and immune response.
  • To evaluate these SNPs as predictive biomarkers for clinical outcomes in mRCC patients treated with sunitinib.

Main Methods:

  • A multicenter, prospective, observational study involving 75 mRCC patients treated with first-line sunitinib.
  • Analysis of 63 SNPs in 31 candidate genes.
  • Assessment of the impact of SNPs on cancer-specific survival (CSS) and progression-free survival (PFS).

Main Results:

  • rs2243250 (IL4) and rs5275 (PTGS2) SNPs were significantly associated with shorter CSS.
  • Allele C of rs5275 correlated with higher PTGS2 expression, indicating functional relevance.
  • Combined SNP models (e.g., rs5275 with rs7651265 or rs2243250) showed improved predictive value for PFS and CSS.

Conclusions:

  • The study identified novel SNP biomarkers (rs5275, rs2243250) associated with sunitinib treatment outcomes in mRCC.
  • The functional variant rs5275 and two-SNP models show potential as clinically relevant predictive biomarkers.
  • These findings could enhance personalized management strategies for mRCC patients undergoing sunitinib therapy.

More Related Videos

The Use of Reverse Phase Protein Arrays RPPA to Explore Protein Expression Variation within Individual Renal Cell Cancers12:22

The Use of Reverse Phase Protein Arrays RPPA to Explore Protein Expression Variation within Individual Renal Cell Cancers

Published on: January 22, 2013

34.2K
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

8.0K

Related Concept Videos

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
60
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
51
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K